TUDCA

Last Updated: September 28 2022

TUDCA is a water soluble bile acid. It shows great potency in treating cholestasis (bile acid backup in the liver) as the water soluble bile acids counteract the toxicity of regular bile acids. Can also protect and rehabilitate the liver, and general protects cells; very promising molecule.

TUDCA is most often used for

Summary

Tauroursodeoxycholic acid, more commonly referred to as TUDCA, is a bile salt that is found natrually occurring in the body. When regular bile salts reach the intestines, they can be metabolized by bacteria into UDCA and then later bound to a taurine molecule to become TUDCA.

TUDCA is a water-soluble bile salt, which is in contrast to regular bile salts possessing both water soluble and fat soluble ends and conferring a detergent effect. This is good for the bile salt's biological purpose (emulsifying fats in the intestines to help with absorption) but when bile acids back up in the liver, a clinical state called cholestasis which occurs when the liver is unhealthy, these bile salts can be damaging to cells by destroying the membranes and signalling for cell death. TUDCA and other water soluble bile salts like UDCA compete with this toxicity and thus indirectly protect cells from death.

Additionally, it seems that TUDCA is able to reduce stress to any cell's Endoplasmic Reticulum; an organelle in cells that serves as a highway from the nucleus out into the cytoplasm, and aids in folding proteins. Through reducing ER stress, TUDCA has been implicated in a wide range of beneficial metabolic effects such as reducing insulin resistance and diabetes, and being a neurological protection agent. However, usages of TUDCA beyond the liver are preliminary whereas usage of TUDCA for helping an already harmed liver is quite reliable as TUDCA is used in clinical settings (hospitals) for treating cholestasis.

What else is TUDCA known as?
Note that TUDCA is also known as:
  • TUDCA
  • Tauroursodeoxycholic Acid
TUDCA should not be confused with:
  • Taurine (a moiety on the UDCA part)
Dosage information

10-13mg daily has once been shown to improve liver regenesis rates in a clinically ill population, and may be the lowest estimate of an active oral dose. When looking at improving bile salt composition, a dose around 15-20mg/kg bodyweight TUDCA seems best according to one study.

Benefits have been seen at 1,750mg daily for muscle and liver insulin sensitivity, which is the highest dose used for treatment of fatty liver disease.

Join our supplement information course

Become an Examine Insider for FREE and get a full five-day mini course on supplements. 100% backed by science, we take an independent and unbiased approach to figure out what works (and what's a waste of time and money).

    The only 100% independent company. While everyone sells supplements, we only analyze research.

    Examine Database: TUDCA
    What works and what doesn't?

    Unlock the full potential of Examine

    Get started

    Don't miss out on the latest research

    Become an Examine Insider for FREE to stay on top of the latest nutrition research, supplement myths, and more

      References
      1.^Lepercq P, Hermier D, David O, Michelin R, Gibard C, Beguet F, Relano P, Cayuela C, Juste CIncreasing ursodeoxycholic acid in the enterohepatic circulation of pigs through the administration of living bacteriaBr J Nutr.(2005 Apr)
      2.^Amaral JD, Viana RJ, Ramalho RM, Steer CJ, Rodrigues CMBile acids: regulation of apoptosis by ursodeoxycholic acidJ Lipid Res.(2009 Sep)
      3.^Invernizzi P, Setchell KD, Crosignani A, Battezzati PM, Larghi A, O'Connell NC, Podda MDifferences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosisHepatology.(1999 Feb)
      5.^Zouboulis-Vafiadis I, Dumont M, Erlinger SConjugation is rate limiting in hepatic transport of ursodeoxycholate in the ratAm J Physiol.(1982 Sep)
      6.^Keene CD, Rodrigues CM, Eich T, Linehan-Stieers C, Abt A, Kren BT, Steer CJ, Low WCA bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's diseaseExp Neurol.(2001 Oct)
      7.^Bernales S, Papa FR, Walter PIntracellular signaling by the unfolded protein responseAnnu Rev Cell Dev Biol.(2006)
      8.^Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, Görgün CZ, Hotamisligil GSChemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetesScience.(2006 Aug 25)
      9.^Ben Mosbah I, Alfany-Fernández I, Martel C, Zaouali MA, Bintanel-Morcillo M, Rimola A, Rodés J, Brenner C, Roselló-Catafau J, Peralta CEndoplasmic reticulum stress inhibition protects steatotic and non-steatotic livers in partial hepatectomy under ischemia-reperfusionCell Death Dis.(2010 Jul 8)
      11.^Hertl M, Hertl MC, Malagó M, Broelsch CEIn vivo protection of the pig liver against ischemia/reperfusion injury by tauroursodeoxycholateLangenbecks Arch Surg.(1999 Oct)
      12.^Anderson CD, Upadhya G, Conzen KD, Jia J, Brunt EM, Tiriveedhi V, Xie Y, Ramachandran S, Mohanakumar T, Davidson NO, Chapman WCEndoplasmic reticulum stress is a mediator of posttransplant injury in severely steatotic liver allograftsLiver Transpl.(2011 Feb)
      13.^Rodrigues CM, Spellman SR, Solá S, Grande AW, Linehan-Stieers C, Low WC, Steer CJNeuroprotection by a bile acid in an acute stroke model in the ratJ Cereb Blood Flow Metab.(2002 Apr)
      14.^Amin A, Choi SK, Galan M, Kassan M, Partyka M, Kadowitz P, Henrion D, Trebak M, Belmadani S, Matrougui KChronic inhibition of endoplasmic reticulum stress and inflammation prevents ischaemia-induced vascular pathology in type II diabetic miceJ Pathol.(2012 Jun)
      16.^Falasca L, Tisone G, Palmieri G, Anselmo A, Di Paolo D, Baiocchi L, Torri E, Orlando G, Casciani CU, Angelico MProtective role of tauroursodeoxycholate during harvesting and cold storage of human liver: a pilot study in transplant recipientsTransplantation.(2001 May 15)
      17.^Marzioni M, Francis H, Benedetti A, Ueno Y, Fava G, Venter J, Reichenbach R, Mancino MG, Summers R, Alpini G, Glaser SCa2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ductsAm J Pathol.(2006 Feb)
      18.^Henkel AS, Dewey AM, Anderson KA, Olivares S, Green RMReducing endoplasmic reticulum stress does not improve steatohepatitis in mice fed a methionine- and choline-deficient dietAm J Physiol Gastrointest Liver Physiol.(2012 Jul)
      19.^Panella C, Ierardi E, De Marco MF, Barone M, Guglielmi FW, Polimeno L, Francavilla ADoes tauroursodeoxycholic acid (TUDCA) treatment increase hepatocyte proliferation in patients with chronic liver diseaseItal J Gastroenterol.(1995 Jun)
      21.^Schölmerich J, Becher MS, Schmidt K, Schubert R, Kremer B, Feldhaus S, Gerok WInfluence of hydroxylation and conjugation of bile salts on their membrane-damaging properties--studies on isolated hepatocytes and lipid membrane vesiclesHepatology.(1984 Jul-Aug)
      22.^Oelberg DG, Lester RCellular mechanisms of cholestasisAnnu Rev Med.(1986)
      23.^Attili AF, Angelico M, Cantafora A, Alvaro D, Capocaccia LBile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acidsMed Hypotheses.(1986 Jan)
      24.^Yousef IM, Barnwell S, Gratton F, Tuchweber B, Weber A, Roy CCLiver cell membrane solubilization may control maximum secretory rate of cholic acid in the ratAm J Physiol.(1987 Jan)
      26.^Salen G, Tint GS, Shefer STreatment of cholesterol gallstones with litholytic bile acidsGastroenterol Clin North Am.(1991 Mar)
      27.^Cetta F, Montalto G, Pacchiarotti MCGallstone opacification during cholelitholytic treatmentAm J Gastroenterol.(1997 Mar)
      28.^Diehl AKEpidemiology and natural history of gallstone diseaseGastroenterol Clin North Am.(1991 Mar)
      29.^Attili AF, Capocaccia R, Carulli N, Festi D, Roda E, Barbara L, Capocaccia L, Menotti A, Okolicsanyi L, Ricci G, Lalloni L, Mariotti S, Sama C, Scafato EFactors associated with gallstone disease in the MICOL experience. Multicenter Italian Study on Epidemiology of CholelithiasisHepatology.(1997 Oct)
      31.^Lanzini A, Northfield TCPharmacological treatment of gallstones. Practical guidelinesDrugs.(1994 Mar)
      32.^Portincasa P, Di Ciaula A, Wang HH, Moschetta A, Wang DQMedicinal treatments of cholesterol gallstones: old, current and new perspectivesCurr Med Chem.(2009)
      36.^Paumgartner G, Pauletzki J, Sackmann MUrsodeoxycholic acid treatment of cholesterol gallstone diseaseScand J Gastroenterol Suppl.(1994)
      37.^Bazzoli F, Festi D, Mazzella G, Frabboni R, Zagari RM, Fossi S, Pozzato P, Sottili S, Simoni P, Roda A, et alAcquired gallstone opacification during cholelitholytic treatment with chenodeoxyholic, ursodeoxycholic, and tauroursodeoxycholic acidsAm J Gastroenterol.(1995 Jun)
      39.^Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WCTauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's diseaseProc Natl Acad Sci U S A.(2002 Aug 6)
      40.^Ved R, Saha S, Westlund B, Perier C, Burnam L, Sluder A, Hoener M, Rodrigues CM, Alfonso A, Steer C, Liu L, Przedborski S, Wolozin BSimilar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegansJ Biol Chem.(2005 Dec 30)
      43.^Ramalho RM, Borralho PM, Castro RE, Solá S, Steer CJ, Rodrigues CMTauroursodeoxycholic acid modulates p53-mediated apoptosis in Alzheimer's disease mutant neuroblastoma cellsJ Neurochem.(2006 Sep)
      44.^Ramalho RM, Viana RJ, Castro RE, Steer CJ, Low WC, Rodrigues CMApoptosis in transgenic mice expressing the P301L mutated form of human tauMol Med.(2008 May-Jun)
      45.^Ramalho RM, Ribeiro PS, Solá S, Castro RE, Steer CJ, Rodrigues CMInhibition of the E2F-1/p53/Bax pathway by tauroursodeoxycholic acid in amyloid beta-peptide-induced apoptosis of PC12 cellsJ Neurochem.(2004 Aug)
      46.^Rodrigues CM, Solá S, Brito MA, Brondino CD, Brites D, Moura JJAmyloid beta-peptide disrupts mitochondrial membrane lipid and protein structure: protective role of tauroursodeoxycholateBiochem Biophys Res Commun.(2001 Feb 23)
      47.^Rodrigues CM, Sola S, Nan Z, Castro RE, Ribeiro PS, Low WC, Steer CJTauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in ratsProc Natl Acad Sci U S A.(2003 May 13)
      48.^Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Görgün C, Glimcher LH, Hotamisligil GSEndoplasmic reticulum stress links obesity, insulin action, and type 2 diabetesScience.(2004 Oct 15)
      49.^Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GSA central role for JNK in obesity and insulin resistanceNature.(2002 Nov 21)
      50.^Urano F, Wang X, Bertolotti A, Zhang Y, Chung P, Harding HP, Ron DCoupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1Science.(2000 Jan 28)
      51.^Rieusset J, Chauvin MA, Durand A, Bravard A, Laugerette F, Michalski MC, Vidal HReduction of endoplasmic reticulum stress using chemical chaperones or Grp78 overexpression does not protect muscle cells from palmitate-induced insulin resistanceBiochem Biophys Res Commun.(2012 Jan 6)
      52.^da-Silva WS, Ribich S, Arrojo e Drigo R, Castillo M, Patti ME, Bianco ACThe chemical chaperones tauroursodeoxycholic and 4-phenylbutyric acid accelerate thyroid hormone activation and energy expenditureFEBS Lett.(2011 Feb 4)
      53.^Tang C, Koulajian K, Schuiki I, Zhang L, Desai T, Ivovic A, Wang P, Robson-Doucette C, Wheeler MB, Minassian B, Volchuk A, Giacca AGlucose-induced beta cell dysfunction in vivo in rats: link between oxidative stress and endoplasmic reticulum stressDiabetologia.(2012 May)
      55.^Kars M, Yang L, Gregor MF, Mohammed BS, Pietka TA, Finck BN, Patterson BW, Horton JD, Mittendorfer B, Hotamisligil GS, Klein STauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and womenDiabetes.(2010 Aug)
      56.^Ockenga J, Valentini L, Schuetz T, Wohlgemuth F, Glaeser S, Omar A, Kasim E, duPlessis D, Featherstone K, Davis JR, Tietge UJ, Kroencke T, Biebermann H, Köhrle J, Brabant GPlasma bile acids are associated with energy expenditure and thyroid function in humansJ Clin Endocrinol Metab.(2012 Feb)
      57.^Brufau G, Bahr MJ, Staels B, Claudel T, Ockenga J, Böker KH, Murphy EJ, Prado K, Stellaard F, Manns MP, Kuipers F, Tietge UJPlasma bile acids are not associated with energy metabolism in humansNutr Metab (Lond).(2010 Sep 3)
      58.^Sagar GD, Gereben B, Callebaut I, Mornon JP, Zeöld A, da Silva WS, Luongo C, Dentice M, Tente SM, Freitas BC, Harney JW, Zavacki AM, Bianco ACUbiquitination-induced conformational change within the deiodinase dimer is a switch regulating enzyme activityMol Cell Biol.(2007 Jul)
      59.^Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, Schoonjans K, Bianco AC, Auwerx JBile acids induce energy expenditure by promoting intracellular thyroid hormone activationNature.(2006 Jan 26)
      60.^Zhou L, Liu M, Zhang J, Chen H, Dong LQ, Liu FDsbA-L alleviates endoplasmic reticulum stress-induced adiponectin downregulationDiabetes.(2010 Nov)
      63.^Krishna-Subramanian S, Hanski ML, Loddenkemper C, Choudhary B, Pagès G, Zeitz M, Hanski CUDCA slows down intestinal cell proliferation by inducing high and sustained ERK phosphorylationInt J Cancer.(2012 Jun 15)
      65.^Henzel K, Thorborg C, Hofmann M, Zimmer G, Leuschner UToxicity of ethanol and acetaldehyde in hepatocytes treated with ursodeoxycholic or tauroursodeoxycholic acidBiochim Biophys Acta.(2004 Feb 2)
      66.^Neuman MG, Cameron RG, Shear NH, Bellentani S, Tiribelli CEffect of tauroursodeoxycholic and ursodeoxycholic acid on ethanol-induced cell injuries in the human Hep G2 cell lineGastroenterology.(1995 Aug)
      67.^Leuschner U, Guldutuna S, Bhatti S, Elze A, Imhof M, You T, Zimmer GTUDCA and UDCA are incorporated into hepatocyte membranes: different sites, but similar effectsItal J Gastroenterol.(1995 Sep)
      68.^Angelico M, Tisone G, Baiocchi L, Palmieri G, Pisani F, Negrini S, Anselmo A, Vennarecci G, Casciani CUOne-year pilot study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantationItal J Gastroenterol Hepatol.(1999 Aug-Sep)
      69.^Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders FHigh-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitisHepatology.(2009 Sep)
      70.^Maggs JR, Chapman RWAn update on primary sclerosing cholangitisCurr Opin Gastroenterol.(2008 May)
      71.^O'Brien CB, Senior JR, Arora-Mirchandani R, Batta AK, Salen GUrsodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot studyHepatology.(1991 Nov)
      72.^Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, Weinzierl M, Pape GR, Sauerbruch T, Paumgartner GUrsodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trialHepatology.(1992 Sep)